Although Dr. Saag was a coauthor of the ACR guidelines, he was pleased to see a new commentary on the ACR guidelines published by the Professional Practice Committee of the ASBMR. The review recommends teriparatide or any of the bisphosphonates for high-risk patients, period.
Dr. Saag, who was not involved in the ASBMR review, recommended it as useful reading both for its areas of agreement with the ACR guidelines as well as for raising several patient scenarios in which the ASBMR committee believes the ACR recommendations either do not apply or might be improved upon (J. Bone Miner. Res. 2011;26:1989-96).
Dr. Glüer declared having no financial conflicts regarding the Eli Lilly–funded EuroGIOPs trial. Dr. Saag disclosed that he has received research grants from and serves as a paid consultant to Amgen, Eli Lilly, Merck, and Novartis.
Dr. Kenneth G. Saag noted that an anabolic agent such as teriparatide stimulates osteoblasts to promote new bone formation.
Source Courtesy University of Alabama